QQQ   430.89 (-0.04%)
AAPL   169.28 (-1.97%)
MSFT   416.07 (+0.59%)
META   501.29 (+0.21%)
GOOGL   154.16 (-0.45%)
AMZN   184.02 (+0.22%)
TSLA   156.73 (-2.94%)
NVDA   869.27 (+1.08%)
AMD   163.29 (+1.85%)
NIO   3.80 (-2.31%)
BABA   69.53 (-1.54%)
T   15.98 (-1.60%)
F   12.06 (-1.39%)
MU   120.22 (-0.95%)
GE   154.21 (+0.33%)
CGC   6.66 (-4.58%)
DIS   113.89 (+0.83%)
AMC   2.65 (+7.29%)
PFE   25.85 (-0.23%)
PYPL   63.70 (+0.30%)
XOM   119.08 (-0.50%)
QQQ   430.89 (-0.04%)
AAPL   169.28 (-1.97%)
MSFT   416.07 (+0.59%)
META   501.29 (+0.21%)
GOOGL   154.16 (-0.45%)
AMZN   184.02 (+0.22%)
TSLA   156.73 (-2.94%)
NVDA   869.27 (+1.08%)
AMD   163.29 (+1.85%)
NIO   3.80 (-2.31%)
BABA   69.53 (-1.54%)
T   15.98 (-1.60%)
F   12.06 (-1.39%)
MU   120.22 (-0.95%)
GE   154.21 (+0.33%)
CGC   6.66 (-4.58%)
DIS   113.89 (+0.83%)
AMC   2.65 (+7.29%)
PFE   25.85 (-0.23%)
PYPL   63.70 (+0.30%)
XOM   119.08 (-0.50%)
QQQ   430.89 (-0.04%)
AAPL   169.28 (-1.97%)
MSFT   416.07 (+0.59%)
META   501.29 (+0.21%)
GOOGL   154.16 (-0.45%)
AMZN   184.02 (+0.22%)
TSLA   156.73 (-2.94%)
NVDA   869.27 (+1.08%)
AMD   163.29 (+1.85%)
NIO   3.80 (-2.31%)
BABA   69.53 (-1.54%)
T   15.98 (-1.60%)
F   12.06 (-1.39%)
MU   120.22 (-0.95%)
GE   154.21 (+0.33%)
CGC   6.66 (-4.58%)
DIS   113.89 (+0.83%)
AMC   2.65 (+7.29%)
PFE   25.85 (-0.23%)
PYPL   63.70 (+0.30%)
XOM   119.08 (-0.50%)
QQQ   430.89 (-0.04%)
AAPL   169.28 (-1.97%)
MSFT   416.07 (+0.59%)
META   501.29 (+0.21%)
GOOGL   154.16 (-0.45%)
AMZN   184.02 (+0.22%)
TSLA   156.73 (-2.94%)
NVDA   869.27 (+1.08%)
AMD   163.29 (+1.85%)
NIO   3.80 (-2.31%)
BABA   69.53 (-1.54%)
T   15.98 (-1.60%)
F   12.06 (-1.39%)
MU   120.22 (-0.95%)
GE   154.21 (+0.33%)
CGC   6.66 (-4.58%)
DIS   113.89 (+0.83%)
AMC   2.65 (+7.29%)
PFE   25.85 (-0.23%)
PYPL   63.70 (+0.30%)
XOM   119.08 (-0.50%)
OTCMKTS:TCNNF

Trulieve Cannabis (TCNNF) Stock Price, News & Analysis

$11.03
-0.25 (-2.22%)
(As of 04/15/2024 ET)
Today's Range
$10.54
$11.39
50-Day Range
$8.38
$13.05
52-Week Range
$3.42
$13.75
Volume
449,436 shs
Average Volume
589,778 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.38
TCNNF stock logo

About Trulieve Cannabis Stock (OTCMKTS:TCNNF)

Trulieve Cannabis Corp., together with its subsidiaries, operates as a cannabis retailer. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, creams, balms, salves, lotions, vaporizers, batteries, cartridge, concentrates, topicals, capsules, synringes, tinctures, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It also operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida.

TCNNF Stock Price History

TCNNF Stock News Headlines

Trulieve Cannabis Corp. (OTCMKTS:TCNNF) Short Interest Update
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Trulieve Announces April 2024 Event Participation
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Holders Of Trulieve Should Sell It
Recap: Trulieve Cannabis Q4 Earnings
See More Headlines
Receive TCNNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trulieve Cannabis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/16/2024
Next Earnings (Estimated)
5/08/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:TCNNF
Fax
N/A
Employees
5,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$54.38
High Stock Price Target
$132.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+393.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Ms. Kimberly Rivers (Age 46)
    Founder, Chairman & CEO
    Comp: $739.44k
  • Mr. Eric Raymond Powers III (Age 55)
    J.D., Chief Legal Officer & Corporate Secretary
    Comp: $507.76k
  • Mr. Timothy Morey (Age 61)
    Chief Sales Officer
    Comp: $404.76k
  • Mr. Kyle Landrum (Age 38)
    Chief Production Officer
    Comp: $411.96k
  • Mr. Wes Getman
    Chief Financial Officer
  • Ms. Marie Zhang
    Chief Operating Officer
  • Ms. Joy Malivuk (Age 49)
    VP & Chief Accounting Officer
  • Mr. Nilyum Jhala
    Chief Technology Officer
  • Mr. Jason Barry Pernell (Age 46)
    Chief Information Officer
    Comp: $182.5k
  • Ms. Christine Hersey
    Director of Investor Relations

TCNNF Stock Analysis - Frequently Asked Questions

Should I buy or sell Trulieve Cannabis stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trulieve Cannabis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCNNF shares.
View TCNNF analyst ratings
or view top-rated stocks.

What is Trulieve Cannabis' stock price target for 2024?

2 brokers have issued 1-year price objectives for Trulieve Cannabis' shares. Their TCNNF share price targets range from $6.00 to $132.00. On average, they expect the company's share price to reach $54.38 in the next twelve months. This suggests a possible upside of 393.0% from the stock's current price.
View analysts price targets for TCNNF
or view top-rated stocks among Wall Street analysts.

How have TCNNF shares performed in 2024?

Trulieve Cannabis' stock was trading at $5.21 at the beginning of the year. Since then, TCNNF shares have increased by 111.7% and is now trading at $11.03.
View the best growth stocks for 2024 here
.

Are investors shorting Trulieve Cannabis?

Trulieve Cannabis saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 373,600 shares, a decrease of 19.0% from the March 15th total of 461,500 shares. Based on an average trading volume of 857,600 shares, the days-to-cover ratio is presently 0.4 days.
View Trulieve Cannabis' Short Interest
.

When is Trulieve Cannabis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TCNNF earnings forecast
.

How were Trulieve Cannabis' earnings last quarter?

Trulieve Cannabis Corp. (OTCMKTS:TCNNF) issued its quarterly earnings data on Monday, November, 15th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.27 by $0.13.

How do I buy shares of Trulieve Cannabis?

Shares of TCNNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TCNNF) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners